Business Context and Reporting Period
uniQure N.V. (QURE) is a gene therapy company focused on developing single treatments for rare and devastating diseases. This Form 10-Q covers the quarterly period ended June 30, 2025. The company operates as an accelerated filer and is incorporated in the Netherlands. As of July 24, 2025, there were 54,866,930 ordinary shares outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenues | $5.3 million | $6.8 million |
| Net Loss | $(37.7) million | $(81.4) million |
| Net Loss Per Share (Basic & Diluted) | $(0.69) | $(1.49) |
| Cash and Cash Equivalents | $253.8 million | $253.8 million (Balance Sheet) |
| Total Current Assets | $408.6 million | $408.6 million |
| Total Liabilities | $588.9 million | $588.9 million |
| Shareholders' Deficit | $(4.0) million | $(4.0) million |
| Long-Term Debt | $51.8 million | $51.8 million |
| Royalty Financing Liability | $455.3 million | $455.3 million |
Operating Cash Flow: Net cash used in operating activities was $84.0 million for the six months ended June 30, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased to $5.3 million in Q2 2025 from $11.1 million in Q2 2024. This was primarily due to the cessation of contract manufacturing and collaboration revenues following the divestiture of commercial manufacturing activities (the "Lexington Transaction") in July 2024. License revenues from CSL Behring increased to $5.3 million from $1.9 million.
- Reduced Net Loss: Net loss improved to $37.7 million in Q2 2025 from $56.3 million in Q2 2024. This improvement was driven by a significant net foreign currency gain of $18.6 million (compared to a loss of $1.0 million in the prior year) and reduced operating expenses.
- Expense Reduction: Research and development (R&D) expenses increased slightly to $35.4 million from $33.7 million, driven by BLA preparation for AMT-130. However, Selling, General, and Administrative (SG&A) expenses decreased to $13.5 million from $15.8 million due to workforce reductions and the manufacturing divestiture.
- Financing Activity: In the first half of 2025, the company raised approximately $80.5 million in net proceeds through a follow-on public offering of ordinary shares.
Guidance, Outlook, and Risks
- AMT-130 (Huntington's Disease): The FDA granted Breakthrough Therapy designation in April 2025. The company has aligned with the FDA on an accelerated approval pathway and expects to present 3-year follow-up data in Q3 2025 to support a potential Biologics License Application (BLA) submission.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investment securities ($377.0 million as of June 30, 2025) will fund operations into the second half of 2027. Additional funding will be required for the commercialization of AMT-130.
- Key Risks:
- Regulatory Uncertainty: Reliance on accelerated approval pathways and external control data for AMT-130; potential changes in FDA leadership or policy.
- Manufacturing Dependence: Post-Lexington Transaction, the company relies on Genezen for manufacturing, introducing supply chain and quality control risks.
- Capital Needs: Continued net losses and the need for significant capital to fund late-stage development and commercialization.
- Contingent Consideration: Potential milestone payments of up to $168.0 million related to the acquisition of uniQure France SAS (AMT-260 program).
Investor Verification Checklist
- Verify the timeline and regulatory requirements for the AMT-130 BLA submission, specifically the reliance on external control data.
- Confirm the status of the Lexington Transaction and the operational stability of the new manufacturing partner, Genezen.
- Monitor the company's cash burn rate against the projected runway into late 2027.
- Review the terms of the Royalty Financing Agreement and the impact of the effective interest rate on future interest expenses.
- Assess the progress of the AMT-260 (Epilepsy) and AMT-191 (Fabry) clinical trials and associated milestone payment triggers.